Velaglucerase Alfa (VPRIV®)

Assessment Status Rapid review complete
Drug Velaglucerase Alfa
Brand VPRIV®
Indication For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.
Assessment Process
Rapid review commissioned 26/04/2011
Rapid review completed 20/06/2011
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.